دورية أكاديمية
أعرض في EDS

Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.

التفاصيل البيبلوغرافية
العنوان: Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.
المؤلفون: Quaye L; Gynaecological Oncology Department, UCL EGA Institute for Women's Health, University College London, London, UK., Song H, Ramus SJ, Gentry-Maharaj A, Høgdall E, DiCioccio RA, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Wozniak E, Doherty JA, Rossing MA, Ness RB, Moysich KB, Høgdall C, Blaakaer J, Easton DF, Ponder BA, Jacobs IJ, Menon U, Whittemore AS, Krüger-Kjaer S, Pearce CL, Pharoah PD, Gayther SA
مؤلفون مشاركون: Ovarian Cancer Association Consortium
المصدر: British journal of cancer [Br J Cancer] 2009 Mar 24; Vol. 100 (6), pp. 993-1001. Date of Electronic Publication: 2009 Feb 24.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: Genetic Predisposition to Disease* , Oncogenes* , Polymorphism, Single Nucleotide*, Ovarian Neoplasms/*genetics, Adult ; Aged ; Class I Phosphatidylinositol 3-Kinases ; Female ; Genes, erbB-2 ; Genotype ; Haplotypes ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Middle Aged ; Phosphatidylinositol 3-Kinases/genetics ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins/genetics
مستخلص: Low-moderate risk alleles that are relatively common in the population may explain a significant proportion of the excess familial risk of ovarian cancer (OC) not attributed to highly penetrant genes. In this study, we evaluated the risks of OC associated with common germline variants in five oncogenes (BRAF, ERBB2, KRAS, NMI and PIK3CA) known to be involved in OC development. Thirty-four tagging SNPs in these genes were genotyped in approximately 1800 invasive OC cases and 3000 controls from population-based studies in Denmark, the United Kingdom and the United States. We found no evidence of disease association for SNPs in BRAF, KRAS, ERBB2 and PIK3CA when OC was considered as a single disease phenotype; but after stratification by histological subtype, we found borderline evidence of association for SNPs in KRAS and BRAF with mucinous OC and in ERBB2 and PIK3CA with endometrioid OC. For NMI, we identified a SNP (rs11683487) that was associated with a decreased risk of OC (unadjusted P(dominant)=0.004). We then genotyped rs11683487 in another 1097 cases and 1792 controls from an additional three case-control studies from the United States. The combined odds ratio was 0.89 (95% confidence interval (CI): 0.80-0.99) and remained statistically significant (P(dominant)=0.032). We also identified two haplotypes in ERBB2 associated with an increased OC risk (P(global)=0.034) and a haplotype in BRAF that had a protective effect (P(global)=0.005). In conclusion, these data provide borderline evidence of association for common allelic variation in the NMI with risk of epithelial OC.
References: Cancer. 1998 Mar 15;82(6):1088-95. (PMID: 9506354)
Nat Genet. 1999 Jan;21(1):99-102. (PMID: 9916799)
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W621-5. (PMID: 16845085)
Br J Cancer. 2008 Jan 29;98(2):282-8. (PMID: 18219286)
Hum Hered. 2002;53(2):79-91. (PMID: 12037407)
Cancer. 2003 Jul 1;98(1):66-73. (PMID: 12833457)
Oncogene. 1996 May 16;12(10):2171-6. (PMID: 8668343)
Genomics. 1994 Dec;24(3):472-7. (PMID: 7713498)
Cell. 1999 Jan 8;96(1):121-30. (PMID: 9989503)
Am J Hum Genet. 1998 Mar;62(3):676-89. (PMID: 9497246)
J Pathol. 2004 Jun;203(2):617-9. (PMID: 15141374)
J Natl Cancer Inst. 2008 Jul 2;100(13):962-6. (PMID: 18577746)
Int J Cancer. 2008 Jul 15;123(2):380-388. (PMID: 18431743)
Clin Cancer Res. 2004 Apr 1;10(7):2473-81. (PMID: 15073127)
J Pathol. 2004 Mar;202(3):336-40. (PMID: 14991899)
Cancer Res. 2006 Oct 15;66(20):10220-6. (PMID: 17047088)
Bioinformatics. 2005 Jul 15;21(14):3176-8. (PMID: 15879453)
Br J Cancer. 2006 Jan 30;94(2):318-22. (PMID: 16421597)
N Engl J Med. 1997 Apr 17;336(16):1125-30. (PMID: 9099656)
Nat Genet. 2002 May;31(1):33-6. (PMID: 11984562)
Nucleic Acids Res. 2008 Jan;36(Database issue):D825-9. (PMID: 18086700)
Annu Rev Biochem. 1998;67:481-507. (PMID: 9759495)
Science. 2002 Jun 21;296(5576):2225-9. (PMID: 12029063)
Mol Hum Reprod. 2006 Nov;12(11):671-6. (PMID: 16973828)
Cancer Res. 2007 Apr 1;67(7):3027-35. (PMID: 17409409)
Science. 2002 May 31;296(5573):1655-7. (PMID: 12040186)
Cancer Detect Prev. 1988;11(3-6):139-49. (PMID: 3292041)
Am J Hum Genet. 1999 Oct;65(4):1021-9. (PMID: 10486320)
N Engl J Med. 2000 Jul 13;343(2):78-85. (PMID: 10891514)
Cancer Res. 2001 Mar 15;61(6):2420-3. (PMID: 11289108)
Gynecol Oncol. 2003 Apr;89(1):31-6. (PMID: 12694651)
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1589-94. (PMID: 15466974)
Gynecol Oncol. 2004 Dec;95(3):570-5. (PMID: 15581965)
Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56. (PMID: 18086757)
Hum Hered. 2003;55(1):27-36. (PMID: 12890923)
J Natl Cancer Inst. 2005 Jan 5;97(1):51-9. (PMID: 15632380)
Future Oncol. 2006 Apr;2(2):257-74. (PMID: 16563094)
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
Gynecol Oncol. 2003 Aug;90(2):378-81. (PMID: 12893203)
J Biol Chem. 2002 Jun 7;277(23):20965-73. (PMID: 11916966)
Nat Genet. 2005 Nov;37(11):1217-23. (PMID: 16244653)
Leuk Res. 2007 Jan;31(1):27-32. (PMID: 16764926)
Hum Mutat. 2007 May;28(5):525-6. (PMID: 17397054)
Bioinformatics. 2005 Jan 15;21(2):263-5. (PMID: 15297300)
Cancer. 1997 Apr 15;79(8):1581-6. (PMID: 9118042)
Am J Hum Genet. 2005 Sep;77(3):337-45. (PMID: 16080110)
PLoS One. 2007 Mar 07;2(3):e268. (PMID: 17342202)
Proteins. 2006 Mar 1;62(4):1125-32. (PMID: 16372356)
معلومات مُعتمدة: CA71766 United States CA NCI NIH HHS; 11021 United Kingdom CRUK_ Cancer Research UK; N01 PC067010 United States PC NCI NIH HHS; R01 CA095023 United States CA NCI NIH HHS; 19275 United Kingdom CRUK_ Cancer Research UK; C8804/A7058 United Kingdom CRUK_ Cancer Research UK; R01 CA063464 United States CA NCI NIH HHS; U01 CA063464 United States CA NCI NIH HHS; CA61132 United States CA NCI NIH HHS; 10118 United Kingdom CRUK_ Cancer Research UK; P01 CA017054 United States CA NCI NIH HHS; 11022 United Kingdom CRUK_ Cancer Research UK; G0801875 United Kingdom MRC_ Medical Research Council; 10119 United Kingdom CRUK_ Cancer Research UK; R01CA095023 United States CA NCI NIH HHS; 10124 United Kingdom CRUK_ Cancer Research UK; P30 CA016056 United States CA NCI NIH HHS; R01 CA087538 United States CA NCI NIH HHS; CA16056 United States CA NCI NIH HHS; K07-CA80668 United States CA NCI NIH HHS; R03 CA113148 United States CA NCI NIH HHS; R03-CA113148 United States CA NCI NIH HHS; R01 CA87538 United States CA NCI NIH HHS; K07 CA080668 United States CA NCI NIH HHS; CA63464 United States CA NCI NIH HHS; P30 CA014089 United States CA NCI NIH HHS; CA17054 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Intracellular Signaling Peptides and Proteins)
0 (KRAS protein, human)
0 (NMI protein, human)
0 (Proto-Oncogene Proteins)
EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases)
EC 2.7.1.137 (PIK3CA protein, human)
EC 2.7.11.1 (BRAF protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
EC 3.6.5.2 (ras Proteins)
تواريخ الأحداث: Date Created: 20090226 Date Completed: 20090401 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC2661781
DOI: 10.1038/sj.bjc.6604947
PMID: 19240718
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1827
DOI:10.1038/sj.bjc.6604947